Boston Scientific price target raised to $85 from $79 at Citi

Citi raised the firm’s price target on Boston Scientific to $85 from $79 and keeps a Buy rating on the shares post the Q1 report. Not only did the company exceed on the revenue and earnings, it did so on key segments, raising 2024 guidance early in the year, the analyst tells investors in a research note.